SEC Tracker
Get the app

RadNet RDNT

RadNet FY 2024: revenue $1.8B, up 13%; diluted EPS $0.04

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers RadNet reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$1.8B+13% from $1.6B in FY 202310-K income statement, on EDGAR
  2. Net income$2.8M−8% from $3.0M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS$0.04−20% from $0.05 in FY 202310-K income statement, on EDGAR
  4. Cash and cash equivalents$740.0M+116% from $342.6M in FY 202310-K balance sheet, on EDGAR
  5. Cash from operations$233.0M+6% from $220.9M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when RadNet files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8071 and related industry codes: the same peer list as the financial tables.

  1. Caris Life Sciences CAI public float $3.9B, Jun 30, 2025
  2. Guardant Health GH public float $6.2B, Jun 30, 2025
  3. GRAIL GRAL public float $1.9B, Jun 30, 2025
  4. Lumexa Imaging Holdings LMRI
  5. Veracyte VCYT public float $1.7B, Jun 30, 2025